422 related articles for article (PubMed ID: 30339049)
1. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
Knuckles MLF; Levi E; Soung J
J Dermatolog Treat; 2019 Aug; 30(5):430-434. PubMed ID: 30339049
[No Abstract] [Full Text] [Related]
2. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
3. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
[TBL] [Abstract][Full Text] [Related]
4. Real-world use of apremilast for patients with psoriasis in Japan.
Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
[TBL] [Abstract][Full Text] [Related]
5. Apremilast for the management of moderate to severe plaque psoriasis.
Vangipuram R; Alikhan A
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):349-360. PubMed ID: 28276777
[TBL] [Abstract][Full Text] [Related]
6. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
[TBL] [Abstract][Full Text] [Related]
7. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
Armstrong A; Levi E
J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
Ighani A; Georgakopoulos JR; Zhou LL; Walsh S; Shear N; Yeung J
J Cutan Med Surg; 2018; 22(3):290-296. PubMed ID: 29373924
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
12. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
13. Real-World Experience With Apremilast in Treating Psoriasis.
Mayba JN; Gooderham MJ
J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis.
Bianchi L; Del Duca E; Romanelli M; Saraceno R; Chimenti S; Chiricozzi A
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1121-8. PubMed ID: 27376729
[TBL] [Abstract][Full Text] [Related]
15. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
Paller AS; Hong Y; Becker EM; de Lucas R; Paris M; Zhang W; Zhang Z; Barcellona C; Maes P; Fiorillo L
J Am Acad Dermatol; 2020 Feb; 82(2):389-397. PubMed ID: 31408686
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
Gottlieb AB; Matheson RT; Menter A; Leonardi CL; Day RM; Hu C; Schafer PH; Krueger JG
J Drugs Dermatol; 2013 Aug; 12(8):888-97. PubMed ID: 23986162
[TBL] [Abstract][Full Text] [Related]
18. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Sobell JM; Foley P; Toth D; Mrowietz U; Girolomoni G; Goncalves J; Day RM; Chen R; Yosipovitch G
Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
[TBL] [Abstract][Full Text] [Related]
19. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM
Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
Papp KA; Kaufmann R; Thaçi D; Hu C; Sutherland D; Rohane P
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]